{
    "clinical_study": {
        "@rank": "28314", 
        "arm_group": [
            {
                "arm_group_label": "Test group", 
                "arm_group_type": "Experimental", 
                "description": "Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment"
            }, 
            {
                "arm_group_label": "Control group: adjuvant therapy", 
                "arm_group_type": "No Intervention", 
                "description": "Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression\n      of hepatocarcinoma after non-radical hepatectomy."
        }, 
        "brief_title": "Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatic Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Disease Progression", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Prospective, Multicenter, Open-labeled, Parallel -controlled Clinical Study, to evaluate\n      the efficacy and safety of Huaier Granule for prevention of disease progression of\n      hepatocarcinoma after non-radical hepatectomy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: \u2265 18 and \u2264 75 years, both male and female;\n\n          2. Non-radical hepatectomy has been performed for hepatocellular carcinoma;\n\n          3. The hepatocellular carcinoma has been confirmed by pathological examination;\n\n          4. The liver and kidney function satisfies the following conditions within 15 days after\n             surgery (excluding day 15): aspartate aminotransferase(AST), glutamic-oxalacetic\n             transaminase(ALT)<3 upper limit of normal(ULN), total bilirubin \u22642 ULN, serum\n             creatinine <1.5 ULN;\n\n          5. Other laboratory tests meet the following requirements within 15 days after surgery\n             (excluding day 15): Hb\u22659g/dl, platelet count\u226560\u00d7109/L, neutrophil count> 2.5\u00d7109/L;\n\n          6. The expected survival time \u226512 weeks;\n\n          7. The subjects volunteer to sign the informed consent.\n\n        Exclusion Criteria:\n\n          1. Non-hepatocellular carcinoma patients;\n\n          2. Those who received radical hepatectomy;\n\n          3. Those with hepatic decompensation;\n\n          4. Pregnant or lactating women;\n\n          5. Those with HIV infection or AIDS-associated diseases;\n\n          6. Those with severe acute and chronic diseases, such as infection, diabetes cardiac\n             insufficiency, pulmonary insufficiency, renal insufficiency;\n\n          7. Those who can not take drugs by oral route; or those develop serious adverse drug\n             reaction;\n\n          8. Drug abusers or those with psychological or mental diseases that may interfere with\n             study compliance;\n\n          9. Conditions that are considered not suitable for this study investigators."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1680", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760616", 
            "org_study_id": "HE-201102"
        }, 
        "intervention": {
            "arm_group_label": "Test group", 
            "description": "Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..", 
            "intervention_name": "Huaier Granule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Huaier Granule;", 
            "After non-radical hepatectomy;", 
            "Prevention of Disease Progression of Hepatocarcinoma;", 
            "Safety."
        ], 
        "lastchanged_date": "January 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wuhan", 
                    "country": "China", 
                    "state": "Hubei"
                }, 
                "name": "Tongji Hospital Affiliated to Tongji Medical College, Huazhong"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multicenter, Open-labeled, Parallel -Controlled Clinical Study Investigating Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy", 
        "overall_official": {
            "affiliation": "Huazhong University of Science and Technology", 
            "last_name": "Xiaoping Chen, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time to significant progression after surgery, including recurrence of local tumor, intrahepatic and extrahepatic metastasis, etc; and to evaluation of  postoperative survival period.", 
            "measure": "Time to significant progression after surgery", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760616"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "On week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132 and 144, assess the scores of Eastern Cooperative Oncology Group(ECOG) and quality of life questionnaire(QLQ)-C30 scale.", 
                "measure": "ECOG and QLQ-C30 scores", 
                "safety_issue": "Yes", 
                "time_frame": "Week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132, 144"
            }, 
            {
                "description": "On week 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132 and 144, give examination of B ultrasonic for Liver, X-ray for chest. If there is a suspected recurrence or metastases, will give enhancement CT/MRI examination for liver and chest; if no recurrence or metastases, will at least give enhancement CT/MRI examination for liver and chest every year.", 
                "measure": "Iconography assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Week 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132, 144"
            }, 
            {
                "description": "On week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132 and 144, monitor Alpha-fetoprotein quantitation.", 
                "measure": "Alpha-fetoprotein quantitation and related biochemical indicators", 
                "safety_issue": "Yes", 
                "time_frame": "Week 8, 16, 24, 32, 40, 48, 60, 72, 84, 96, 108, 120, 132, 144"
            }
        ], 
        "source": "Qidong Gaitianli Medicines Co., Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Huazhong University of Science and Technology", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Qidong Gaitianli Medicines Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}